kalvista pharma - Search News

News

KalVista, Hereditary Angioedema and FDA

Reuters on MSN · 1d

US FDA approves KalVista Pharma's swelling disorder drug, shares rise

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 17% in premarket trading.

Business Wire · 2d

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel

PharmExec · 23h

FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.

Fierce Pharma1d

KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly

After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...

6d

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results